Skip to main content
Tech.euFundingExplorerBeta

Desentum

A biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

Total raised
€22M
€21,900,000
Funding rounds
3
Investors
2
distinct backers
Active since
2018-09
latest 2024-02

Funding by year

EUR raised per year

Signals

High confidence
Raise-next likelihood24
base rate 30% for Other
  • Overdue vs cohort gap
  • Up-round momentum
  • Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
  • 3 rounds raised
  • 15y since founding

Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

3 rounds
DateStageAmountInvestors
2024-02-20Other€12MSpringvest OyView deal →
2022-01-21Other€8.0MSpringvest OyView deal →
2018-10-01Grant€1.9MEUView deal →

Investors

2

Similar companies

same sector or country